We have used intravenous cis-platinum chemotherapy in the treatment of three patients with basal cell carcinoma of the lid extending into the orbit. Cis-platinum chemotherapy caused a reduction in tumour size and thereby delayed surgery in all cases. It allowed for local resection in one case, appeared to delay a patient's exenteration in a second case, and was used prior to radiotherapy in a third case. While not curative, cis-platinum may be useful as an adjuvant to decrease tumour mass prior to local excision and for patients who refuse or must delay exenteration.
Basal cell carcinoma is the commonest malignant tumour of the eyelids.' Surgical excision is the treatment of choice because of the high rate of cure and excellent cosmetic and functional results.2"'4 However, there are circumstances when surgical resection is impossible or when a patient refuses to have surgery. Other forms of treatment have been described including radiotherapy, chemotherapy, phototherapy, drug therapy, immunotherapy, and cryotherapy. '11-4 Radiotherapy has been successful in the treatment of basal cell carcinoma, but associated lash loss, dry eye, keratopathy, cataract, retinopathy, and optic neuropathy have been reported.'516 While cryotherapy has been used for small superficial tumours, newer methods including immunotherapy, phototherapy, and drug therapy are still being investigated.2""2 (15 August 1985) . Note the tumour-associated lateral ectropion. (B) A post-treatment external photograph ofthe nodular basal cell carcinoma on the right lower lid two months after the onset of intravenous cis-platinum chemotherapy (15 October 1985) . Note the marked reduction in size ofthe superficial tumour and partial resolution ofthe lateral ectropion. Chemotherapy of basal cell carcinoma has also been tried as treatment for tumours involving the orbit and adnexa.'71' A total of eight cases of chemotherapy as a primary treatment for basal cell carcinoma in the eyelids have been reported.'7 18 We describe our experience in treating three cases of basal cell carcinoma involving the orbit and eyelids with intravenous cis-platinum. An incisional biopsy revealed basal cell carcinoma. Our patient refused surgical resection and was offered the alternative of cis-platinun chemotherapy.
Materials
Cis-platinum was administered without complication in July 1985. Two weeks later the tumour had regressed in size by approximately 30% (Fig 1B) . A second course of cis-platinum was given in August 1985, and two weeks later the tumour was reduced in size by approximately 40%. We noted that the patient suffered mild, transient mental confusion associated with the chemotherapy and antiemetic therapy. Repeat computed tomography of the orbit confirmed a reduction in the size of the tumour (Fig 2B) , and a third course of cis-platinum was administered in October 1985. Again treatment was com- Figure 3 Large mass extendingfrom the medial canthus across the entire lower lid to 5 We undertook extensive lid, orbit, and sinus resection in an attempt to excise the tumour. Multiple frozen sections were positive for tumour, and I-125 brachytherapy implants were placed in the frontal sinus and against the remaining ethmoidal sinuses as a 30 Gy boost to external radiotherapy. Then 60 Gy of external beam radiation was delivered to the orbit and sinuses. Eighteen months after radiotherapy there has been no evidence of new tumour growth. Discussion This is the second series of cases recording a reduction in the size of basal cell carcinomas of the lids and orbit associated with cis-platinum chemotherapy. All three patients we treated were considered to have partial regression of their tumour. In one of the three cases partial regression allowed for local excision with negative margins, in another delayed exenteration, and in the third it postponed radiotherapy.
There are significant side effects associated with intravenous cis-platinum chemotherapy. 2634 As seen in case 3 in our report, dose related and cumulative renal insufficiency is the major toxic effect.26 Thus pre-existing renal insufficiency is a contraindication to its use. Careful attention to fluid status, creatinine clearance, and creatinine levels is mandatory.
Severe nausea and vomiting are frequently Figure 4B further treatment. Our data confirm the observations of Luxenberg and Guthrie that lid and periocular basal cell carcinoma will respond to intravenous cis-platinum with adriamycin.'718 In their cases the commonest outcome was a partial reduction in tumour size requiring additional treatment to control tumour spread. Our experience was similar in that cis-platinum alone was not curative, yet it served as a helpful adjunct in the management of basal cell carcinoma of the eyelids and orbit.
